BRAINSTORM CELL THERAPEUTICS (BCLI) Stock Price, Quote, News and Overview
NASDAQ:BCLI - Nasdaq - US10501E3009 - Common Stock - Currency: USD
BCLI Quote, Performance and Key Statistics
1.24
-0.01 (-0.8%)
The current stock price of BCLI is 1.24 USD. In the past month the price increased by 2.48%. In the past year, price decreased by -82.41%.
BCLI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.65 | 338.27B | ||
| AMGN | AMGEN INC | 14.06 | 156.91B | ||
| GILD | GILEAD SCIENCES INC | 14.12 | 135.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 116.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.7 | 55.99B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.93B | ||
| ARGX | ARGENX SE - ADR | 99.99 | 35.11B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.72 | 28.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.35B | ||
| NTRA | NATERA INC | N/A | 22.77B | ||
| BIIB | BIOGEN INC | 8.41 | 19.50B | ||
| INSM | INSMED INC | N/A | 17.85B |
Related stock screener links
About BCLI
Company Profile
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. The company is headquartered in New York City, New York and currently employs 27 full-time employees. The company went IPO on 2003-05-28. The firm is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The firm's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.
Company Info
BRAINSTORM CELL THERAPEUTICS
1325 Avenue Of Americas, 28th Floor
New York City NEW YORK 10019 US
CEO: Chaim Lebovits
Employees: 27
Phone: 12014880460
BRAINSTORM CELL THERAPEUTICS / BCLI FAQ
What is the stock price of BRAINSTORM CELL THERAPEUTICS today?
The current stock price of BCLI is 1.24 USD. The price decreased by -0.8% in the last trading session.
What is the ticker symbol for BRAINSTORM CELL THERAPEUTICS stock?
The exchange symbol of BRAINSTORM CELL THERAPEUTICS is BCLI and it is listed on the Nasdaq exchange.
On which exchange is BCLI stock listed?
BCLI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BRAINSTORM CELL THERAPEUTICS stock?
7 analysts have analysed BCLI and the average price target is 12.75 USD. This implies a price increase of 928.5% is expected in the next year compared to the current price of 1.24. Check the BRAINSTORM CELL THERAPEUTICS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BRAINSTORM CELL THERAPEUTICS worth?
BRAINSTORM CELL THERAPEUTICS (BCLI) has a market capitalization of 9.85M USD. This makes BCLI a Nano Cap stock.
How many employees does BRAINSTORM CELL THERAPEUTICS have?
BRAINSTORM CELL THERAPEUTICS (BCLI) currently has 27 employees.
What are the support and resistance levels for BRAINSTORM CELL THERAPEUTICS (BCLI) stock?
BRAINSTORM CELL THERAPEUTICS (BCLI) has a support level at 1.24 and a resistance level at 1.33. Check the full technical report for a detailed analysis of BCLI support and resistance levels.
Should I buy BRAINSTORM CELL THERAPEUTICS (BCLI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BCLI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BCLI, evaluating the profitability, health, valuation and growth aspects
- BRAINSTORM CELL THERAPEUTICS (BCLI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BRAINSTORM CELL THERAPEUTICS (BCLI) Sales and EPS estimates to see what analysts future expectations are.
- BRAINSTORM CELL THERAPEUTICS (BCLI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BRAINSTORM CELL THERAPEUTICS (BCLI) Insider and Institutional Ownership to learn about the owners and their transactions.
- BRAINSTORM CELL THERAPEUTICS (BCLI) Stock Chart to make your own analysis
- BRAINSTORM CELL THERAPEUTICS (BCLI) Latest news and press-releases to stay up to date.
Does BRAINSTORM CELL THERAPEUTICS (BCLI) stock pay dividends?
BCLI does not pay a dividend.
When does BRAINSTORM CELL THERAPEUTICS (BCLI) report earnings?
BRAINSTORM CELL THERAPEUTICS (BCLI) will report earnings on 2025-08-12.
What is the Price/Earnings (PE) ratio of BRAINSTORM CELL THERAPEUTICS (BCLI)?
BRAINSTORM CELL THERAPEUTICS (BCLI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.07).
What is the Short Interest ratio of BRAINSTORM CELL THERAPEUTICS (BCLI) stock?
The outstanding short interest for BRAINSTORM CELL THERAPEUTICS (BCLI) is 3.14% of its float. Check the ownership tab for more information on the BCLI short interest.
BCLI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BCLI. When comparing the yearly performance of all stocks, BCLI is a bad performer in the overall market: 96.86% of all stocks are doing better.
BCLI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BCLI. BCLI has a bad profitability rating. Also its financial health evaluation is rather negative.
BCLI Financial Highlights
Over the last trailing twelve months BCLI reported a non-GAAP Earnings per Share(EPS) of -2.07. The EPS increased by 21.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -310.45% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BCLI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to BCLI. The Buy consensus is the average rating of analysts ratings from 7 analysts.